Finance

In this article

In this photo illustration a Johnson & Johnson logo is seen in front of a medical syringe and a vial with coronavirus vaccine.
Pavlo Gonchar | SOPA Images | LightRocket | Getty Images

Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.

In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.48 per share vs $2.27 expected.
  • Revenue: $23.31 billion vs $22.21 billion expected.

The company’s share price was up nearly 1% in premarket trading following the report.

This is a developing story. Please check back for updates.

Articles You May Like

Gold set for fourth week of gains amid Trump policy jitters
Oil prices steady as investors weigh impact of Trump tariffs
The GBPUSD is the biggest mover today with the run to the upside breaching key technicals
Sellers are making play in the AUDUSD. Can they keep the momentum to the downside going?
Was yesterday the capitulation in NVDA? [Video]